Japanese pharmaceutical company Takeda invested over 98 million euros in the production of pharmaceuticals in Russia, 477 million rubles of which were assigned to the production of innovation orphan drug Ixazomib named Ninlaro for patients with multiple myeloma (blood cancer). This information was provided to TASS by a company’s press service representative at the opening ceremony of the drug manufacturing site of the plant in Yaroslavl.
UEC-Saturn (member of the United Engine Corporation, UEC) and the French Safran Aircraft Engines (member of the Safran Group) concluded a master agreement for development of a modification of the SaM146 engine for remotorization of the Russian amphibian aircraft Be-200. The news was reported by the press-office of UEC.
Construction of 450 MW Huadian-Teninskaya CCPP has been completed in Yaroslavl Region Pre-commissioning works have been started at the facility that is expected to reduce the region’s power shortages
International pharmaceutical company Takeda announces launching the production of innovation drug Ixazomib for patients with multiple myeloma (blood cancer) at its plant in Yaroslavl. The official start-up is scheduled for the 1-st of August.
European pharmaceutical company Besins Healthcare will invest about 500 million rubles in the construction of a pharmaceutical factory in the Yaroslavl region.
Besins Healthcare SA will build a new drug manufacturing plant in Yaroslavl Region. The new facility will produce Utrogestan which is included in the Russia's Essential Drugs List. Project investment will account for RUB 500 mln, the launch of commercial production is scheduled for 2019.